

NOT FOR PUBLICATION

COMMERCIAL IN CONFIDENCE

Note of the meeting with Armour Pharmaceutical Company Ltd to discuss
"Factorate", held at 12 noon on Monday 6 October 1986 in Market Towers.

Present: Mr Hale Dr Rodell (Armour)
Dr Jones Dr Harris (Armour)
Dr Jefferys
Mr Hagger
Dr Moore
Dr Rotblat
Mr Dunleavy
Mr Lye

1. Dr Rodell said that he had spoken to the President of Armour, who had agreed that the company would withdraw both Factorate and High Potency Factorate.
2. Monoclalte, another Armour factor VIII product which uses the same heat treatment process as Factorate, holds a clinical trial exemption certificate. Dr Rodell said that the company would provide data to show that this was a safe product. He stressed that Armour attached great importance to this clinical trial.
3. The company agreed to submit a letter, dated 6 October 1986, formally surrendering the two product licences.
4. The company agreed to write to all haemophiliac centres. Armour will clear the letter and a draft press release with the Department this afternoon (6 October).
5. Armour will also telephone today the eight Regional Haemophiliac Centres, telling them of the withdrawal and asking them to pass the information to the haemophiliac centres under their jurisdiction. The company will confirm this by calling the centres as soon as possible.
6. The company will also inform the Haemophilia Society of its decision. Dr Moore will confirm.
7. Dr Moore will inform Wales, Scotland and Northern Ireland.
8. Dr Jefferys will inform the CPMP, WHO and FDA by telex.

cc. Ms McKessack Mr Cashman
Mr Fisher Mr Nilsson
Mr Langsden Dr Johnson
Miss Coker Dr Wills
Mr Rayner Mr Stewart
Dr Harris Dr Purves
Dr Pickles Miss Simkins
Mr Franks Ms Murphy
Dr Mann Ms Mayhew

GRO-C

David Lye.
MB1C
Room 1421 MT
Ext GRO-C

6 October 1986.